Oral anticoagulation with warfarin is significantly influenced by steroids and CYP2C9 polymorphisms in children with cancer

被引：15

作者：

Ruud, Ellen ^{[1
]}

Holmstrom, Henrik ^{[1
]}

Bergan, Stein ^{[2
]}

Wesenberg, Finn ^{[1
]}

机构：

[1] Rikshosp Radiumhosp Med Ctr, Dept Paediat, Oslo, Norway

[2] Rikshosp Radiumhosp Med Ctr, Dept Med Biochem, Oslo, Norway

来源：

PEDIATRIC BLOOD & CANCER | 2008年 / 50卷 / 03期

关键词：

anticoagulation; cancer; INR; warfarin;

D O I：

10.1002/pbc.21133

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Clinical management of warfarin therapy is complex, and dosing algorithms do [lot include genetic factors or interactions with other drugs for warfarin close determinations. We evaluated the interaction or. warfarin and CYP2C9 polymorphisms and concomitant corticosteroids in 29 children with cancer. Children with heterozygous polymorphisms of CYP2C9 achieved target INR sooner and more frequently had INR above the target level, compared to children without mutations. Children on concomitant steroids had significantly lower warfarin requirements. Thus, awareness of CYP2C9 genotype and steroid-induced responsiveness to warfarin may be important when administrating oral anticoagulation in children.

引用

页码：710 / 713

页数：4

共 17 条

[1] New anticoagulants: A pediatric perspective [J].

Balasa, VV .

PEDIATRIC BLOOD & CANCER, 2005, 45 (06) :741-752

[2] Oral anticoagulation therapy in children [J].

Bonduel, Mariana M. .

THROMBOSIS RESEARCH, 2006, 118 (01) :85-94

[3] Potentiation of vitamin K antagonists by high-dose intravenous methylprednisolone [J].

Costedoat-Chalumeau, N ;

Amoura, Z ;

Aymard, G ;

Sevin, O ;

Wechsler, B ;

Cacoub, P ;

Du, LTH ;

Diquet, B ;

Ankri, A ;

Piette, JC .

ANNALS OF INTERNAL MEDICINE, 2000, 132 (08) :631-635

[4] A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin [J].

D'Andrea, G ;

D'Ambrosio, RL ;

Di Perna, P ;

Chetta, M ;

Santacroce, R ;

Brancaccio, V ;

Grandone, E ;

Margaglione, M .

BLOOD, 2005, 105 (02) :645-649

[5]

Daly Ann K, 2003, Semin Vasc Med, V3, P231

[6] Prospective, Randomized Pilot Trial of Model-Based Warfarin Dose Initiation using CYP2C9 Genotype and Clinical Data [J].

Hillman, Michael A. ;

Wilke, Russell A. ;

Yale, Steven H. ;

Vidaillet, Humberto J. ;

Caldwell, Michael D. ;

Glurich, Ingrid ;

Berg, Richard L. ;

Schmelzer, John ;

Burmester, James K. .

CLINICAL MEDICINE & RESEARCH, 2005, 3 (03) :137-145

[7] Clinical consequences of cytochrome P4502C9 polymorphisms [J].

Kirchheiner, J ;

Brockmöller, J .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (01) :1-16

[8] DOUBLE-BLIND RANDOMIZED TRIAL OF VERY-LOW-DOSE WARFARIN FOR PREVENTION OF THROMBOEMBOLISM IN STAGE-IV BREAST-CANCER [J].

LEVINE, M ;

HIRSH, J ;

GENT, M ;

ARNOLD, A ;

WARR, D ;

FALANGA, A ;

SAMOSH, M ;

BRAMWELL, V ;

PRITCHARD, KI ;

STEWART, D ;

GOODWIN, P .

LANCET, 1994, 343 (8902) :886-889

[9] Antithrombotic therapy in children [J].

Monagle, P ;

Chan, A ;

Massicotte, P ;

Chalmers, E ;

Michelson, AD .

CHEST, 2004, 126 (03) :645S-687S

[10] Warfarin therapy in children who require long-term total parenteral nutrition [J].

Newall, F ;

Barnes, C ;

Savoia, H ;

Campbell, J ;

Monagle, P .

PEDIATRICS, 2003, 112 (05) :E386-E388

← 1 2 →